Tuberculosis Medication Adherence among TB-HIV Co-infected Persons undergoing Concomitant Treatment in Selected Local Governments in a North Central State in Nigeria
Abstract:
The
aim of this study was to investigate Tuberculosis medication adherence among patients
undergoing concomitant treatment for HIV and TB in selected Local Government Areas
of Benue State, Nigeria. The study adopts a cross-sectional descriptive survey design
using a quantitative instrument to generate information on factors that have significant
influence on TB medication adherence among persons using concurrent TB-HIV medication.
The
overall rate of adherence was 72.7%. Perception of TB disease and TB medication,
Family and peer support, Health Service factors, Media and Policy were positively
and significantly associated with adherence practice among participants in the study.
The study revealed a high prevalence of knowledge (96%) (9.6±0.86) about TB disease
among respondents, although knowledge had no significant association with TB medication
adherence among the study group. In relation to the socio-demographic characteristics
of respondents, analysis of age, gender and level of education did not reveal any
significant association with medication adherence and likewise marital status or
living arrangement.
The
study concluded that factors associated with adherence TB medication adherence among
persons undergoing concomitant treatment are factors that could be modified with
concerted efforts and strategies by stakeholders and health programs to improve
adherence levels and cause a decline in the level of non-adherence (27.3%) reported
in the study. The study recommends further studies to assess factors that could
provide evidence for interventions to help persons suffering from co-morbidities
like TB and HIV.
References:
[1].
World
Health Organization (2015). The end TB strategy. Geneva, Switzerland: World Health
Organization; 2015. Retrieved from
https://www.who.int/tb/strategy/end-tb/en/external
icon.
[2].
Ofoegbu,
O.S. & Odume, B.B. (2015). Treatment outcome of tuberculosis patients at National
Hospital Abuja Nigeria: a five-year retrospective study. South African Family Practice, 57, 1
[3].
Ifebunandu,
N.A. & Ukwaja, K.N. (2012). Tuberculosis treatment default in a large tertiary
care hospital in urban Nigeria: prevalence, trend, timing and predictors. Journal of Infection and Public Health,
5, 340–345.
[4].
Glynn,
J. R., Murray, J, Bester, A., Nelson, G., Shearer, S., Sonnenberg, P. (2010). High
rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis.
Journal of Infectious Diseases, 201, 704–711.
[5].
Getahun,
H., Gunneberg, C., Granich, R. & Nunn, P. (2010). HIV infection-associated tuberculosis:
the epidemiology and the response. Clinical
Infectious Disease, 50(3), 201–207.
[6].
World
Health Organization (2018). Latent TB infection updated and consolidated guidelines
for programmatic management. Geneva, Switzerland: World Health Organization; 2018.
Retrieved from https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/external
icon
[7].
Bruchfeld,
J., Correia-Neves, M., & Källenius, G. (2015). Tuberculosis and HIV Coinfection.
Cold Spring Harbor perspectives in medicine, 5(7), 017871.
[8].
Castelnuovo,
B.A. (2010). Review of compliance to anti tuberculosis treatment and risk factors
for defaulting treatment in Sub Saharan Africa. African Health Sciences, 10, 320–324.
[9].
Dooley,
K.E, Lahlou, O., Ghali, I., Knudsen, J., Elmessaoudi, D., Cherkaoui, I., Aouad,
R. E. (2011) Risk factors for tuberculosis treatment failure, default, or relapse
and outcomes of retreatment in Morocco. BMC Public Health, 11, 140.
[10].
Fang,
X. H., Dan, Y. L., Liu, J., Jun, L., Zhang, Z. P., Kan, X. H. & Wu, G. C. (2019).
Factors influencing completion of treatment among pulmonary tuberculosis patients.
Patient Preference and Adherence, 13, 491–496.
[11].
Getahun,
B., Ameni, G., Medhin, G. & Biadgilign, S. (2013). Treatment outcome of tuberculosis
patients under directly observed treatment in Addis Ababa, Ethiopia. Brazillian
Journal of Infectious Diseases, 17, 521–8.
[12].
Edginton,
M. E., Satane, C. S. & Goldstein, S.J. (2012). Patients' beliefs: Do they affect
tuberculosis control? A study in a rural district of South Africa. International
Journal of Tuberculosis and Lung Disease, 6(12), 1075-82.
[13].
Nuwaha,
F. (2010). High compliance in an ambulatory tuberculosis treatment programme in
a rural community of Uganda. International
Journal of Tuberculosis & Lung Disease, 3(1), 79-81.
[14].
Kebede,
A. & Tajure, W. N. (2012). Medication adherence and its determinants among patients
on concomitant tuberculosis and antiretroviral therapy in south west Ethiopia. New American Journal of Medical Science,
4, 67–71.
[15].
Gebremariam,
M. K., Bjune, G. A., Frich, J. C. (2010). Barriers and facilitators of adherence
to TB treatment in patients on concomitant TB and HIV treatment: A qualitative study.
BMC Public Health, 10, 651.
[16].
Mekonnen,
D., Derbie, A., Desalegn, E. (2015). TB/HIV co-infections and associated factors
among patients on directly observed treatment short course in Northeastern Ethiopia:
a 4-year retrospective study. BMC Research
Notes, 8, 666-674.
[17].
Muñoz-Sellart,
M., Cuevas, L., Tumato, M., Merid, Y. & Yassin, M. (2010). Factors associated
with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. International Journal of Tuberculosis & Lung
Diseases, 14, 973–979.
[18].
Ngamvithayapong,
J., Winkvist, A. & Diwan, V. (2010). High AIDS awareness may cause tuberculosis
patient delay: Results from an HIV epidemic area, Thailand. AIDS, 14(10),
1413-1419.
[19].
Kaona,
F. A., Tuba, M., Siziva, S. & Sikaona, L. (2014). An assessment of factors contributing
to treatment adherence and knowledge of TB transmission among patients on TB treatment.
BMC Public Health, 29(4), 68.
[20].
Liam,
C. K., Lim, K.H., Wong, C. M. & Tang, B.G. (2011). Attitudes and knowledge of
newly diagnosed tuberculosis patients regarding the disease, and factors affecting
treatment compliance. International Journal of Tuberculosis and Lung Disease,
3(4), 300-309.